Cromatic
The marketplace under the science

Here is a fact about biotech that sounds made up but isn't: some of the most expensive science on Earth gets outsourced the way you'd find a plumber. A scientist needs an assay run, a molecule synthesized, a trial managed. So they ask around. They email a former colleague. Someone knows someone at a contract research organization, a CRO, and a handshake later a million-dollar project is underway - tracked, if you can call it that, in a spreadsheet and a very long email thread.

This is the problem Cromatic decided to stare at directly. The company, founded in 2022 and based in San Francisco, runs a curated marketplace connecting biotech and pharma companies with vetted CROs and, increasingly, the contract development and manufacturing organizations (CDMOs) that actually make things. On top of the marketplace sits software: vendor discovery, project tracking, data storage and analysis, collaboration tools, contract negotiation, and milestone-based payments. The pitch is unglamorous and, for that reason, convincing - take the coordination tax out of outsourced research.

The interesting thing about a coordination tax is that nobody sends you an invoice for it. It hides in the weeks spent finding the right vendor, the status updates that never arrive, the invoices reconciled by hand. Insiders stop noticing it because it's just how the industry works. Cromatic's founders noticed because one of them had paid it personally.

That's chief executive Ann Lin, who holds a PhD in genetics from Stanford and was previously a scientific co-founder at Meliora Therapeutics. Her co-founder and chief technology officer, Anne Chen, came from Meta - the pairing you'd want if your thesis is that hard science needs consumer-grade software. Lin's one-line diagnosis of the market is the whole company in a sentence: finding a CRO is still mostly by word of mouth.

What makes the bet plausible is that outsourced science isn't a niche. It's the plumbing of an entire industry. Drug discovery, foodtech, agtech - a huge share of the actual work happens outside the company that owns the program. Whoever runs the software layer beneath those transactions sits, quietly, underneath a lot of very consequential decisions. That is exactly the kind of position investors like. When AgFunder and LifeX Ventures led Cromatic's $5.3 million seed round in November 2023, the syndicate that piled in behind them read like a greatest-hits list: Lux Capital, Accel, Kleiner Perkins, FJ Labs, Not Boring Capital, Worklife Ventures, What If Ventures. The round was oversubscribed.

Money follows a certain logic here. A marketplace's health isn't measured only in revenue but in gross flow - how much value moves across it. On that metric Cromatic moved fast, reporting more than $15 million in R&D budget under management within months of launch, across roughly 50 biotech clients and a network of 100-plus vetted CROs. The company makes money the way marketplaces do: buyers pay an annual subscription plus per-transaction referral fees, while CROs pay no subscription and a referral fee per deal. Incentives point the same direction - get the right match, close it, and get paid on the flow.

Then there's the part that's genuinely fun. Cromatic's logo is drawn from the endoplasmic reticulum, the organelle inside every cell responsible for folding proteins and quality-checking them before they ship. It is an almost too-perfect metaphor for what the product claims to do - take the messy raw output of research procurement and fold it into something structured and vetted. It also tells you who the branding is for. This is a logo designed by people who assume their customers passed cell biology.